Korenberg Matthew E

LGND President & COO Korenberg sold 16,047 shares for $1.6M (Sep 20–23) at $102.35 avg; now holds 50.8K shares.

Matthew E Korenberg executed 4 separate sales totaling 16,047 shares for $1,642,358.76 between September 20–23, 2024, reducing his holdings by 24.0% from 66.8K to 50.8K shares at an average price of $102.35. The current stock price of $99.54 is 9.6% below the 52-week high of $110.11, and the company faces significant headwinds: annual revenue declined 33.1% year-over-year, the latest quarterly revenue is $41.5M with a net loss of $51.9M, and the P/E ratio stands at 43.09. Korenberg's prior 5 trades at LGND show a pattern of recent selling activity (Aug 22–26), and while his cross-ticker track record shows 0 of 9 prior sells were well-timed at the 90-day mark, the deteriorating fundamentals and substantial reduction in his equity stake warrant attention to whether leadership confidence in near-term recovery is limited.

LGND President & COO Korenberg sells 18,858 shares for $1,986,420.12 in 5 transactions (Aug 22-26)

Matthew E Korenberg executed 5 separate sales totaling 18,858 shares for $1,986,420.12 between August 22–26, 2024, reducing his holdings from 68,368 shares to 49,510 shares (a -27.6% reduction). The sales occurred at prices ranging from $104.09–$106.32, with a blended average of $105.34. At this ticker, his prior three measurable sales (May 2024) each showed negative 30-day and positive 90-day returns (ranging -4.4% to -5.2% at 30 days, +16.2% to +18.5% at 90 days), with 0 of 3 prior sells well-timed at the 90-day mark. The company is trading -4.5% from its 52-week high of $110.11 and has posted negative net income of $-51,911,000.00 (latest quarter) against annual revenue growth of -33.1%, reflecting operational pressure. The transaction coincides with no earnings announcement flagged in the data, placing the sale outside a typical earnings-driven context.

Korenberg (President & COO) sold 18.2K LGND shares at $98.50; now holds 68.4K. Stock up 20.1% in 90 days, -33.1% revenue YoY.

Matthew E. Korenberg, President & COO of Ligand Pharmaceuticals, sold 18,245 shares at $98.50 on 2024-08-09, reducing his position by 21.1% to 68,368 shares post-transaction. The sale occurred as the stock has recovered 20.1% over the prior 90 days and trades -6.4% from its 52-week high of $110.11. However, Ligand's fundamentals present headwinds: the company posted net income of -$51.9M against revenue of $41.5M in the latest quarter, and annual revenue has contracted 33.1% year-over-year. Korenberg's cross-ticker track record shows 3 prior sales with a 90-day well-timed rate of 0.00%, and his 3 prior sales at LGND specifically each resulted in positive 90-day returns (+17.1%, +16.2%, +18.5%), meaning those sales consistently underperformed as the stock rose afterward; absent a scheduled trading plan disclosure, the pattern of poorly-timed exits invites scrutiny against the backdrop of deteriorating operating performance.